Artificial Intelligence–Enabled Multi-Omics for Predicting Immune Checkpoint Inhibitor Response and Resistance
Journal of Multidisciplinary Healthcare · 2026-02 · Volume 19 · 1-20
DOI: 10.2147/jmdh.s572089 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Multidisciplinary Healthcare, 2026-02. Verfasst von Xiaodong Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, People's Republic of China. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 140 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) have reshaped oncology, yet overall response rates remain modest and resistance is common, driven by tumor heterogeneity and evolving tumor-immune crosstalk. Established biomarkers (PD-L1, tumor mutational burden, microsatellite instability) provide incomplete prediction. Multi-omics profiling across genomic, transcriptomic, proteomic, epigenomic, metabolomic and microbiomic layers offers a systems-level view of malignant and immune states, uncovering determinants of ICI efficacy such as lineage plasticity, stromal remodeling, immunometabolic reprogramming and microbiome-associated immune modulation. Artificial intelligence (AI) is uniquely positioned to fuse these heterogeneous data, learn non-linear cross-layer signatures, and enable interpretable predictions using approaches such as SHAP and Grad-CAM. Representative models link routine histology or imaging to molecular phenotypes, stratify patients beyond single biomarkers, and may nominate rational combinations that target oncogenic pathways, lactate-driven immune suppression, or the gut microbiome. In this narrative review, we synthesize recent AI-multi-omics advances for response modeling, immune-relevant tumor subtyping, and clinical translation, including radiomics/pathomics integration and liquid-biopsy-based monitoring, as well as emerging applications in toxicity risk prediction. We also discuss barriers to implementation-platform heterogeneity, limited prospective validation, bias, interpretability and cost-and outline future directions, including single-cell and spatial multi-omics integration, federated learning and generative modeling to improve robustness and equity of precision immunotherapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University, Zhuzhou, People's Republic of China.
ORCID-Profile: Xiaodong Wang
Zitieren
APA
Wang, X., He, J., Ding, G., Tang, Y., & Wang, Q. (2026). Artificial Intelligence–Enabled Multi-Omics for Predicting Immune Checkpoint Inhibitor Response and Resistance. Journal of Multidisciplinary Healthcare, Volume 19, 1-20. https://doi.org/10.2147/jmdh.s572089
Vancouver
Wang X, He J, Ding G, Tang Y, Wang Q. Artificial Intelligence–Enabled Multi-Omics for Predicting Immune Checkpoint Inhibitor Response and Resistance. Journal of Multidisciplinary Healthcare. 2026;Volume 19:1-20. doi:10.2147/jmdh.s572089
BibTeX
@article{Wang2026,
author = {Wang, Xiaodong and He, Jing and Ding, Gouping and Tang, Yixuan and Wang, Qianqian},
title = {Artificial Intelligence–Enabled Multi-Omics for Predicting Immune Checkpoint Inhibitor Response and Resistance},
journal = {Journal of Multidisciplinary Healthcare},
year = {2026},
volume = {Volume 19},
pages = {1--20},
doi = {10.2147/jmdh.s572089}
}
EUVIMED